EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting emerging amino acid dependencies and transporters in cancer therapy

Alfred Akinlalu, Emmanuel Ogberefor, Tommy Gao, Dali Sun

Frontiers in Pharmacology · 19.11.2025 · 16

DOI: 10.3389/fphar.2025.1717414 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.11.2025. Verfasst von Alfred Akinlalu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical focus, Department of Electrical and Computer Engineering, University of Denver, Denver, CO, United States. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amino acid metabolism is an important vulnerability in cancer. Established strategies such as arginine depletion, glutaminase inhibition, tryptophan-kynurenine modulation, and methionine restriction have shown that these pathways can be targeted in patients. At the same time, clinical trials reveal two consistent challenges: tumors can adapt by redirecting their metabolism, and reliable biomarkers are needed to identify patients who are most likely to benefit. Recent studies point to additional amino acids with translational potential. In pancreatic cancer, histidine and isoleucine supplementation has been shown in preclinical models to be selectively cytotoxic to tumor cells while sparing normal counterparts. In glioblastoma, threonine codon-biased protein synthesis programs that support growth; in other contexts, lysine breakdown suppresses interferon signaling through changes in chromatin structure; and alanine released from stromal cells sustains mitochondrial metabolism and therapy resistance. These dependencies are closely tied to amino acid transporters, which act as both nutrient entry points and measurable biomarkers. In this review, we summarize current evidence on histidine, isoleucine, threonine, lysine, and alanine as emerging metabolic targets, and discuss opportunities and challenges for clinical translation, with emphasis on transporter biology, biomarker development, and therapeutic combinations.

Schlagwörter

Stichwörter der Autor:innen

SLC transportersamino acid metabolismamino acid transporterscancer therapydietary modulationglutaminase inhibitionmetabolic targetingnutritional intervention

Autor:innen und Institutionen

  • Biomedical focus, Department of Electrical and Computer Engineering, University of Denver, Denver, CO, United States.
  • Knoebel Institute of Healthy Aging, University of Denver, Denver, CO, United States.
  • Center for Advanced Biosensing Engineering (CABE), Deparment of Electrical and Computer Engineering, University of Denver, Denver, CO, United States.

Zitieren

APA

Akinlalu, A., Ogberefor, E., Gao, T., & Sun, D. (2025). Targeting emerging amino acid dependencies and transporters in cancer therapy. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1717414

Vancouver

Akinlalu A, Ogberefor E, Gao T, Sun D. Targeting emerging amino acid dependencies and transporters in cancer therapy. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1717414

BibTeX
@article{Akinlalu2025,
  author = {Akinlalu, Alfred and Ogberefor, Emmanuel and Gao, Tommy and Sun, Dali},
  title = {Targeting emerging amino acid dependencies and transporters in cancer therapy},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1717414}
}
Kostenlos starten →